Drug Trial Radar · NCT02224573
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
681
Actual
Start
Jun 11, 2015
Primary completion
Sep 24, 2020
Study completion Sep 24, 2020
Sponsor
- Lead sponsor
- GW Research LtdJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- First posted
- Aug 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.
Conditions
- Epilepsy
- Dravet Syndrome
- Lennox-Gastaut Syndrome
Interventions
GWP42003-PDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment GroupTime frame: up to Week 260
- Number of Participants With Clinically Significant Changes in the Indicated Vital Sign Values From the Pre-randomization Baseline of the Core Study at Any Time Post-doseTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Body Mass Index (BMI)Time frame: up to Week 260
- Number of Participants With Clinically Significant Electrocardiogram (ECG) Values at the Pre-randomization Baseline of the Core Study and at Any Time Post-doseTime frame: up to Week 260
- Number of Participants With the Indicated Responses to Questions Regarding Suicidal Ideation and Behavior Using the Children's Columbia-Suicide Severity Rating Scale (C-SSRS) at Day 1 and at Any Time Post-doseTime frame: up to Week 260
- Mean Cannabis Withdrawal Scale Score at End of Taper (EOT), the Post-Taper Safety Call, and at Safety Follow-upTime frame: up to Week 260
- Mean Pediatric Cannabinoid Withdrawal Scale (PCWS) Score at the End of Treatment, the End of Taper, the Post-Taper Safety Call, and at Safety Follow-upTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Red Blood Cells (RBCs) ValuesTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hemoglobin LevelsTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Hematocrit ValuesTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular VolumeTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Erythrocyte Mean Corpuscular HemoglobinTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Platelets, White Blood Cells, Basophils, Eosinophils, Lymphocytes, Monocytes, and NeutrophilsTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in the Percentage of Basophils, Eosinophils, Lymphocytes, Monocytes, and Neutrophils in White Blood Cells (WBCs)Time frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Sodium, Potassium, Blood Urea Nitrogen, Glucose, Calcium, and High-Density Lipoprotein (HDL) CholesterolTime frame: up to week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine (Jaffe), Creatinine (Enzymatic), and BilirubinTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Creatinine Clearance (Schwartz) and Creatinine Clearance (Cockcroft-Gault)Time frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, and Gamma Glutamyl TransferaseTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Albumin and ProteinTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in ProlactinTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin TimeTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Prothrombin International Normalized RatioTime frame: up to Week 260
- Mean Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Insulin-like Growth Factor-1 (IGF-1) LevelsTime frame: up to Week 260
- Mean Subject/Caregiver Global Impression of Change (S/CGIC) ScoreTime frame: Baseline; up to Week 260
- Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Total Seizure FrequencyTime frame: Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, Week 253 to 264, and Last 12 Weeks
- Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Drop Seizure Frequency in Participants With Lennox-Gastaut SyndromeTime frame: Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, and Last 12 Weeks
- Percent Change From the Pre-randomization Baseline of the Core Study to the End of Treatment in Convulsive Seizure Frequency in Participants With Dravet SyndromeTime frame: Baseline; Week 49 to 60, Week 97 to 108, Week 145 to 156, Week 205 to 216, Week 253 to 264, and Last 12 Weeks
- Number of Participants With Convulsive and Non-convulsive Seizures Greater Than 30 Minutes in Duration (Status Epilepticus)Time frame: Baseline; At last 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.